Israeli Anti-Obesity Drug Shown To Have Limited Impact On Habits
This article was originally published in PharmAsia News
Executive Summary
Israel's anti-obestity drug, Histalean, has been shown in an early clinical trial to stem weight gains in participating patients, but not to significant levels